Company news

X4 Pharmaceuticals, Inc. news in 2025

X4 Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

November 5, 2025

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 5, 2025

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

October 27, 2025

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

October 24, 2025

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

October 23, 2025

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

September 17, 2025

Sitryx appoints Adam Mostafa as Chief Financial Officer

September 8, 2025

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

August 13, 2025

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

August 12, 2025

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

April 24, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

April 24, 2025

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

March 11, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

February 19, 2025

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

February 5, 2025

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2025

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

January 23, 2025

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

January 12, 2025

Calls in 2025

Decks in 2025